Lincoln [LINCOLN] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Lincoln Pharmaceuticals Ltd.

NSE
Loading...

Divi's Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Lincoln Pharmaceuticals Ltd. wins in 8 metrics, Divi's Laboratories Ltd. wins in 12 metrics, with 0 ties. Divi's Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Lincoln Pharmaceuticals Ltd. Divi's Laboratories Ltd. Better
P/E Ratio (TTM) 13.91 67.11 Lincoln Pharmaceuticals Ltd.
Price-to-Book Ratio 1.71 10.82 Lincoln Pharmaceuticals Ltd.
Debt-to-Equity Ratio 0.01 0.58 Lincoln Pharmaceuticals Ltd.
PEG Ratio 0.37 4.63 Lincoln Pharmaceuticals Ltd.
EV/EBITDA 9.75 48.63 Lincoln Pharmaceuticals Ltd.
Profit Margin (TTM) 13.47% 24.04% Divi's Laboratories Ltd.
Operating Margin (TTM) 11.95% 29.65% Divi's Laboratories Ltd.
EBITDA Margin (TTM) 11.95% 29.65% Divi's Laboratories Ltd.
Return on Equity 12.26% 14.64% Divi's Laboratories Ltd.
Return on Assets (TTM) 10.33% 12.94% Divi's Laboratories Ltd.
Free Cash Flow (TTM) $737.71M $2.15B Divi's Laboratories Ltd.
Dividend Yield 0.32% 0.91% Divi's Laboratories Ltd.
1-Year Return 16.77% 0.83% Lincoln Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 1.87 16.18 Lincoln Pharmaceuticals Ltd.
Enterprise Value $9.86B $1,635.46B Divi's Laboratories Ltd.
EV/Revenue Ratio 1.51 15.86 Lincoln Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 54.33% 63.71% Divi's Laboratories Ltd.
Revenue per Share (TTM) $325 $388 Divi's Laboratories Ltd.
Earnings per Share (Diluted) $43.85 $93.66 Divi's Laboratories Ltd.
Beta (Stock Volatility) 0.36 0.19 Divi's Laboratories Ltd.

Lincoln Pharmaceuticals Ltd. vs Divi's Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

LINCOLN
DIVISLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Lincoln Pharmaceuticals Ltd.-0.08%-21.06%-8.10%-4.69%17.88%22.97%
Divi's Laboratories Ltd.0.67%-3.26%-1.31%2.02%1.80%2.98%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Lincoln Pharmaceuticals Ltd.16.77%66.94%118.94%336.67%194.12%194.12%
Divi's Laboratories Ltd.0.83%89.86%56.44%484.44%1,625.50%9,907.51%

Performance & Financial Health Analysis: Lincoln Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricLINCOLNDIVISLAB
Market Information
Market Cap i₹12.25B₹1.69T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i51,590253,443
90 Day Avg. Volume i43,780283,911
Last Close₹589.55₹6,576.50
52 Week Range₹440.00 - ₹770.00₹5,636.50 - ₹7,071.50
% from 52W High-23.44%-7.00%
All-Time High₹979.50 (Dec 09, 2024)₹7,071.50 (Jul 08, 2025)
% from All-Time High-39.81%-7.00%
Growth Metrics
Quarterly Revenue Growth0.14%0.12%
Quarterly Earnings Growth0.38%-0.01%
Financial Health
Profit Margin (TTM) i0.13%0.24%
Operating Margin (TTM) i0.12%0.30%
Return on Equity (TTM) i0.12%0.15%
Debt to Equity (MRQ) i0.010.58
Cash & Liquidity
Book Value per Share (MRQ)₹357.45₹580.95
Cash per Share (MRQ)₹115.79₹122.95
Operating Cash Flow (TTM) i₹967.87M₹19.67B
Levered Free Cash Flow (TTM) i₹823.46M₹21.91B
Dividends
Last 12-Month Dividend Yield i0.32%0.91%
Last 12-Month Dividend i₹1.80₹60.00

Valuation & Enterprise Metrics Analysis: Lincoln Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricLINCOLN (Apr 24, 2026)DIVISLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i13.9167.11
Forward P/E iN/A53.75
PEG Ratio i0.374.63
Price to Sales (TTM) i1.8716.18
Price to Book (MRQ) i1.7110.82
Market Capitalization
Market Capitalization i₹12.25B₹1.69T
Enterprise Value i₹9.86B₹1.64T
Enterprise Value Metrics
Enterprise to Revenue i1.5115.86
Enterprise to EBITDA i9.7548.63
Risk & Other Metrics
Beta i0.360.19
Book Value per Share (MRQ) i₹357.45₹580.95

Financial Statements Comparison: Lincoln Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricLINCOLN (2025)DIVISLAB (2025)
Revenue/Sales i6.15B93.25B
Cost of Goods Sold i2.93B38.70B
COGS % of Revenue i47.6%41.5%
Gross Profit i3.23B54.55B
Gross Margin i52.4%58.5%
Research & Development iN/A270.00M
Operating Income (EBIT) i892.06M25.71B
Operating Margin i14.5%27.6%
EBITDA i1.17B33.19B
EBITDA Margin i19.0%35.6%
Pre-Tax Income i1.09B29.16B
Pre-Tax Income % of Revenue i17.7%31.3%
Income Tax i268.42M7.25B
Income Tax % of Revenue i4.4%7.8%
Net Income (Profit) i823.46M21.91B
Profit Margin i13.4%23.5%

Balance Sheet & Liquidity Metrics

MetricLINCOLN (2025)DIVISLAB (2025)
Cash & Equivalents i134.14M4.15B
Total Current Assets i5.00B100.81B
Total Current Assets % of Revenue i81.3%108.1%
Total Current Liabilities i1.06B14.52B
Total Current Liabilities % of Revenue i17.3%15.6%
Long-Term Debt iN/A20.00M
Long-Term Debt % of Revenue i0.0%0.0%
Total Shareholders Equity i6.72B149.69B
Retained Earnings i5.86B134.00B
Retained Earnings % of Revenue i95.2%143.7%
Property, Plant & Equipment i220.84M3.19B

Cash Flow Statement Comparison

MetricLINCOLN (2025)DIVISLAB (2025)
Operating Cash Flow i967.87M19.67B
Operating Cash Flow % of Revenue i15.7%21.1%
Capital Expenditures i-189.07M-14.38B
Free Cash Flow i737.71M2.15B
FCF Margin i12.0%2.3%
Debt Repayment i-694.17MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricLINCOLNDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i20.03M265.47M
Float Shares i9.26M117.72M
% Held by Insiders i55.10%52.04%
% Held by Institutions i1.03%28.65%
% Held by Public i43.87%19.31%

Dividend Analysis & Yield Comparison: Lincoln Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricLINCOLNDIVISLAB
Last 12-Month Dividend i₹1.80₹60.00
Last 12-Month Dividend Yield i0.32%0.91%
3-Year Avg Annual Dividend i₹1.70₹50.00
3-Year Avg Dividend Yield i0.29%0.70%
3-Year Total Dividends i₹5.10₹150.00
Ex-Dividend DateSep 12, 2025Jul 25, 2025